Coherus Oncology Reports Six-Year Survival Data for LOQTORZI Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Should l Buy CHRS?
Coherus Oncology announced compelling six-year overall survival, OS, follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma, RM-NPC. The findings reveal a striking and durable survival advantage that underscores the urgent clinical need to incorporate LOQTORZI with chemotherapy as first-line treatment. In this exploratory post-hoc analysis, patients receiving LOQTORZI plus gemcitabine and cisplatin achieved a median OS of 64.8 months, nearly double that of chemotherapy alone, representing a 31-month improvement and an observed 38% reduction in risk of death. These results, presented at ESMO Asia 2025, signal a step change in cancer patient survival, reinforcing LOQTORZI's role in transforming outcomes for people living with RM-NPC.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CHRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CHRS
Wall Street analysts forecast CHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHRS is 5.50 USD with a low forecast of 4.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.090
Low
4.00
Averages
5.50
High
7.00
Current: 2.090
Low
4.00
Averages
5.50
High
7.00
About CHRS
Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Partners with Coherus for Cancer Trial
- Clinical Trial Collaboration: Johnson & Johnson (JNJ) has agreed to supply Coherus Oncology (CHRS) with its bispecific antibody pasritamig to evaluate its combination with Coherus' monoclonal antibody tagmokitug for a phase 1b trial in metastatic castration-resistant prostate cancer, highlighting the synergistic potential in cancer treatment between the two companies.
- Trial Funding Arrangement: Coherus will sponsor the phase 1b clinical trial, which not only provides a crucial clinical validation opportunity for its product tagmokitug but also has the potential to enhance its market competitiveness through successful trial outcomes.
- Retention of Commercial Rights: Both companies will retain commercial rights to each other's compounds, whether as monotherapies or combination therapies, which helps facilitate independent brand development while laying the groundwork for future collaborations.
- Antibody Characteristics: Pasritamig is considered a T-cell engaging bispecific antibody, while tagmokitug is an anti-CCR8 cytolytic monoclonal antibody, and this technological combination may offer new treatment options for prostate cancer patients, further driving innovation in the biopharmaceutical sector for both companies.
See More
Oncolytics Biotech Strengthens Leadership Amid Oncology Market Surge
- Market Potential: The global oncology therapy market is projected to reach $668 billion by 2034, and Oncolytics Biotech is seizing investment opportunities through execution-focused registration study designs in this rapidly growing sector.
- Leadership Enhancement: Oncolytics Biotech appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to advance the company's registration-directed programs in gastrointestinal cancers.
- Breakthrough Efficacy Data: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients, significantly surpassing the historical 6-11% response rate for chemotherapy alone, indicating its potential in difficult-to-treat populations.
- FDA Study Design Approval: Oncolytics Biotech has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the imminent launch of the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
Oncolytics Biotech Strengthens Leadership for Oncology Trials
- Market Potential: The global oncology therapy market is projected to reach $668 billion by 2034, creating significant investment opportunities for Oncolytics Biotech as it capitalizes on execution-ready platforms in this rapidly growing sector.
- Leadership Strengthening: Oncolytics Biotech appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which is expected to accelerate the company's registration-directed programs in gastrointestinal cancers.
- Breakthrough Efficacy Data: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients, significantly exceeding the historical benchmark of 6-11% for chemotherapy alone, laying a strong foundation for future clinical applications.
- FDA Study Design Approval: Oncolytics Biotech has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the imminent launch of the only immunotherapy registration trial currently planned for this challenging therapeutic area, further solidifying its market position.
See More
Oppenheimer Initiates Coherus Oncology (CHRS) at Outperform with $10 Price Target
- Promise of Anti-CCR8 Antibody: Oppenheimer has upgraded Coherus Oncology (CHRS) to outperform, citing the significant potential of its anti-CCR8 monoclonal antibody tagmokitug for various cancers, with a price target of $10 representing a 529% upside from the January 22 close.
- Significant Stock Surge: Following Oppenheimer's rating, Coherus shares rose approximately 31% in Friday trading, reflecting strong market confidence in its new therapies and positive investor sentiment.
- Clinical Trial Advancements: Tagmokitug is currently in phase 2 trials as a fourth-line treatment for colorectal cancer and in phase 1 for head and neck squamous cell carcinoma, gastric, and esophageal cancers, indicating its potential for multiple applications in cancer treatment.
- Growth Potential in Combination Therapies: Analyst Jay Olson noted that Coherus' sole marketed product, Loqtorizi (toripalimab), a PD-1 inhibitor for nasopharyngeal carcinoma, could see growth as part of combination therapies, further enhancing the company's competitive position in the market.
See More
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
- Coherus Performance: Coherus Oncology, Inc. (CHRS) rose 9.09% in after-hours trading, closing at $1.73 with a $0.14 gain, indicating strong investor confidence in its future prospects.
- Sensei Biotech Surge: Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% after hours, finishing at $12.47 with a $1.14 increase, reflecting positive market expectations for its products.
- uniQure Significant Jump: uniQure N.V. (QURE) posted a 9.96% rise in after-hours trading, closing at $24.95 with a $2.26 gain, suggesting investor optimism regarding its R&D progress.
- IO Biotech Strategic Exploration: Although IO Biotech, Inc. (IOBT) had no fresh news on Thursday, its stock still gained 4.19%, closing at $0.50, indicating market interest in its exploration of strategic alternatives, including potential mergers or asset sales.
See More
GT Biopharma Submits IND for GTB-5550 Targeting $362 Billion Solid Tumor Market
- Market Transformation: The precision medicine sector is projected to grow from $138 billion in 2026 to over $537 billion by 2035, marking a shift towards modular biologics that creates substantial market opportunities for companies like GT Biopharma.
- New Drug Application: GT Biopharma submitted an IND for GTB-5550 to the FDA in December 2025, targeting the B7-H3 protein to treat various solid tumors, which is expected to significantly enhance the company's competitiveness in cancer treatment.
- Clinical Trial Progress: The planned Phase 1 trial for GTB-5550 will evaluate its efficacy across seven distinct metastatic disease cohorts, potentially providing critical clinical data to further advance the company's product pipeline.
- Dual Program Advancement: GT Biopharma is concurrently advancing its Phase 1 trial of GTB-3650, having successfully treated multiple patients with a favorable safety profile, which is expected to significantly expand its addressable patient population.
See More
Johnson & Johnson Partners with Coherus for Cancer Trial
- Clinical Trial Collaboration: Johnson & Johnson (JNJ) has agreed to supply Coherus Oncology (CHRS) with its bispecific antibody pasritamig to evaluate its combination with Coherus' monoclonal antibody tagmokitug for a phase 1b trial in metastatic castration-resistant prostate cancer, highlighting the synergistic potential in cancer treatment between the two companies.
- Trial Funding Arrangement: Coherus will sponsor the phase 1b clinical trial, which not only provides a crucial clinical validation opportunity for its product tagmokitug but also has the potential to enhance its market competitiveness through successful trial outcomes.
- Retention of Commercial Rights: Both companies will retain commercial rights to each other's compounds, whether as monotherapies or combination therapies, which helps facilitate independent brand development while laying the groundwork for future collaborations.
- Antibody Characteristics: Pasritamig is considered a T-cell engaging bispecific antibody, while tagmokitug is an anti-CCR8 cytolytic monoclonal antibody, and this technological combination may offer new treatment options for prostate cancer patients, further driving innovation in the biopharmaceutical sector for both companies.
See More
Oncolytics Biotech Strengthens Leadership Amid Oncology Market Surge
- Market Potential: The global oncology therapy market is projected to reach $668 billion by 2034, and Oncolytics Biotech is seizing investment opportunities through execution-focused registration study designs in this rapidly growing sector.
- Leadership Enhancement: Oncolytics Biotech appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to advance the company's registration-directed programs in gastrointestinal cancers.
- Breakthrough Efficacy Data: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients, significantly surpassing the historical 6-11% response rate for chemotherapy alone, indicating its potential in difficult-to-treat populations.
- FDA Study Design Approval: Oncolytics Biotech has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the imminent launch of the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
Oncolytics Biotech Strengthens Leadership for Oncology Trials
- Market Potential: The global oncology therapy market is projected to reach $668 billion by 2034, creating significant investment opportunities for Oncolytics Biotech as it capitalizes on execution-ready platforms in this rapidly growing sector.
- Leadership Strengthening: Oncolytics Biotech appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which is expected to accelerate the company's registration-directed programs in gastrointestinal cancers.
- Breakthrough Efficacy Data: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients, significantly exceeding the historical benchmark of 6-11% for chemotherapy alone, laying a strong foundation for future clinical applications.
- FDA Study Design Approval: Oncolytics Biotech has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the imminent launch of the only immunotherapy registration trial currently planned for this challenging therapeutic area, further solidifying its market position.
See More
Oppenheimer Initiates Coherus Oncology (CHRS) at Outperform with $10 Price Target
- Promise of Anti-CCR8 Antibody: Oppenheimer has upgraded Coherus Oncology (CHRS) to outperform, citing the significant potential of its anti-CCR8 monoclonal antibody tagmokitug for various cancers, with a price target of $10 representing a 529% upside from the January 22 close.
- Significant Stock Surge: Following Oppenheimer's rating, Coherus shares rose approximately 31% in Friday trading, reflecting strong market confidence in its new therapies and positive investor sentiment.
- Clinical Trial Advancements: Tagmokitug is currently in phase 2 trials as a fourth-line treatment for colorectal cancer and in phase 1 for head and neck squamous cell carcinoma, gastric, and esophageal cancers, indicating its potential for multiple applications in cancer treatment.
- Growth Potential in Combination Therapies: Analyst Jay Olson noted that Coherus' sole marketed product, Loqtorizi (toripalimab), a PD-1 inhibitor for nasopharyngeal carcinoma, could see growth as part of combination therapies, further enhancing the company's competitive position in the market.
See More
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
- Coherus Performance: Coherus Oncology, Inc. (CHRS) rose 9.09% in after-hours trading, closing at $1.73 with a $0.14 gain, indicating strong investor confidence in its future prospects.
- Sensei Biotech Surge: Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% after hours, finishing at $12.47 with a $1.14 increase, reflecting positive market expectations for its products.
- uniQure Significant Jump: uniQure N.V. (QURE) posted a 9.96% rise in after-hours trading, closing at $24.95 with a $2.26 gain, suggesting investor optimism regarding its R&D progress.
- IO Biotech Strategic Exploration: Although IO Biotech, Inc. (IOBT) had no fresh news on Thursday, its stock still gained 4.19%, closing at $0.50, indicating market interest in its exploration of strategic alternatives, including potential mergers or asset sales.
See More
GT Biopharma Submits IND for GTB-5550 Targeting $362 Billion Solid Tumor Market
- Market Transformation: The precision medicine sector is projected to grow from $138 billion in 2026 to over $537 billion by 2035, marking a shift towards modular biologics that creates substantial market opportunities for companies like GT Biopharma.
- New Drug Application: GT Biopharma submitted an IND for GTB-5550 to the FDA in December 2025, targeting the B7-H3 protein to treat various solid tumors, which is expected to significantly enhance the company's competitiveness in cancer treatment.
- Clinical Trial Progress: The planned Phase 1 trial for GTB-5550 will evaluate its efficacy across seven distinct metastatic disease cohorts, potentially providing critical clinical data to further advance the company's product pipeline.
- Dual Program Advancement: GT Biopharma is concurrently advancing its Phase 1 trial of GTB-3650, having successfully treated multiple patients with a favorable safety profile, which is expected to significantly expand its addressable patient population.
See More
